Idiopathic Pulmonary Fibrosis: 8 Years On After Nintedanib and Pirfenidone Approval —What Is on the Horizon?

AbstractPurpose of ReviewThe approval of nintedanib and pirfenidone has changed the treatment landscape of idiopathic pulmonary fibrosis (IPF); however, both drugs only slow disease progression and are burdened by tolerability issues. We summarize the most advanced developmental drugs in IPF, but also mention selected compounds in earlier phases.Recent FindingsSeveral compounds are currently being tested in IPF; the number of trials has increased exponentially in the last 3  years. Four compounds have reached phase 3: BI101550, an oral PDE4B preferential inhibitor; Pamrevlumab, an anticonnective tissue growth factor intravenous monoclonal antibody; Pentraxin-2, a recombinant human form of serum amyloid protein; Treprostinil, a synthetic prostanoid, with an inhaled for mulation, currently used for pulmonary hypertension.SummaryNew drugs are likely to reach the clinic in the near future. This will provide more opportunities for treatment of IPF but will also pose unprecedented challenges regarding drug selection and administration(i.e., sequential vs. combination).
Source: Current Respiratory Care Reports - Category: Respiratory Medicine Source Type: research